Cease K B, Berzofsky J A
Department of Internal Medicine, University of Michigan, Ann Arbor.
Annu Rev Immunol. 1994;12:923-89. doi: 10.1146/annurev.iy.12.040194.004423.
Over a decade has passed since the identification of the human immunodeficiency virus (HIV) as the causative agent of AIDS. During this time, HIV has been extensively characterized, and a variety of vaccine constructs and strategies have been explored. For the most part, these have been driven by successes of the past with other pathogens, or by novel approaches enabled by technologies of the present. With the maturing of our insights into the immunopathology of HIV and basic immunological mechanisms, we are presented with unprecedented opportunities to rationally develop vaccine approaches strategically designed to counter the immunopathology of HIV. As opposed to absolute prevention of infection, the primary goal of these strategies may be to limit infection and to assure a response to infection that prevents disease and transmission. Thus, such vaccines may find utility in both preventive and therapeutic roles. In this paper, we present the background and current state of immunobiology-driven vaccine development for AIDS.
自确定人类免疫缺陷病毒（HIV）为艾滋病的病原体以来，已经过去了十多年。在此期间，HIV已得到广泛的特征描述，并且探索了各种疫苗构建体和策略。在很大程度上，这些都是由过去在其他病原体方面的成功经验，或者由当前技术带来的新方法所推动的。随着我们对HIV免疫病理学和基本免疫机制认识的成熟，我们面临着前所未有的机会，可以合理地开发旨在对抗HIV免疫病理学的战略性疫苗方法。与绝对预防感染不同，这些策略的主要目标可能是限制感染，并确保对感染做出反应以预防疾病和传播。因此，此类疫苗可能在预防和治疗方面都有用途。在本文中，我们介绍了免疫生物学驱动的艾滋病疫苗开发的背景和现状。
